Danaher Completes Acquisitions of Precision NanoSystems and GoSilico to Strengthen End-to-End Biopharma Solutions

WASHINGTON, June 3, 2021 /PRNewswire/ -- June 1, 2021,Danaher Life Sciences Platform Announces Completion of Acquisition of Lipid Nanotechnology CompanyAcquisition of Precision NanoSystems (PNI). PNI is a global expert in technologies and solutions for the development of genetic medicines (including mRNA vaccines and therapeutics), with its headquarters located in Vancouver, Canada. Through this acquisition, PNI'sGenVoy Delivery TechnologyWill complement the existing products and technologies of Danaher's Cytiva and Pall, further accelerating the drug development process.

Danaher Life Sciences Platform Announces Completion of Acquisition of Lipid Nanoparticle Technology Company Precision NanoSystems (PNI)

June 2, 2021,Danaher Operating CompaniesCytiva Announces Completion of Acquisition of German Scientific Software Manufacturer GoSilico, with the aim of further consolidating the company's position in the field of biopharmaceutical manufacturing processesDigitalizationAdvantage: Empowering Customers, Benefiting Patients.

GoSilico Co-founders Dr. Tobias Hahn, Dr. Thiemo Huuk, and Dr. Teresa Baumann

mRNA Therapeutics and Vaccines MarketOverall growth has been rapid, and the development of COVID-19 mRNA vaccines has further accelerated this trajectory. It is anticipated that mRNA technology will be utilized to develop a broader range of vaccines, as well as serve as a therapeutic modality for currently highly intractable diseases, such as cancer and genetic disorders.

Emmanuel Ligner, President of Danaher's Global Biotechnology Group, stated. "With mRNA successfully applied as a mature technology in COVID-19 vaccines, we foresee its tremendous potential in accelerating the development of other therapeutics. Meanwhile, the work completed to date by the PNI team has also helped Cytiva and Pall customers significantly advance their technological development, and with the recent addition of Vanrx to Cytiva, willCollaboratively delivering robust end-to-end solutions for gene therapy innovators., to benefit more patients.”

James Taylor, Co-founder and Chief Executive Officer of Precision NanoSystems, stated, "Over the past decade, PNI has been dedicated to advancing genetic medicine development technologies. Since joining Danaher,Our world-class team is better equipped to support our customers faster and more comprehensively through its integrated technology platforms and specialized expertise in manufacturing breakthrough therapeutics.。The Danaher Life Sciences platform operates globally and serves top-tier clients in the biotechnology industry, providing an excellent opportunity to bring PNI’s innovative technologies to market and expand their reach.”

Prior to this, Danaher had just completed Cytiva's acquisition of Vanrx, a manufacturer of sterile filling machines.

Regarding Cytiva's acquisition of GoSilico, Olivier Loeillot, Vice President of Cytiva, stated: “GoSilico's highly innovative digital solutions will deliver immense value to our customers—by leveraging digital models, they can make better decisions, accelerate process development, and bring new therapies to market faster.”GoSilico’s expert team and solutions will optimally complement Cytiva’s longstanding strengths in chromatography process development and end-to-end bioprocessing.。”

Dr. Thiemo Huuk, Co-founder and Chief Executive Officer of GoSilico, also stated, “Our entire team is delighted to join the Cytiva family. Given Cytiva’s extensive global customer base, our digital modeling technology will benefit more biopharmaceutical companies, ultimately achieving more robust process development and more effective pathways., bringing innovative therapies to patients.”

Danaher Announces Completion of Acquisitions of Precision NanoSystems and GoSilico, Further Strengthening End-to-End Biopharmaceutical Solutions

Process Developmentis the most critical and time-consuming step in the biopharmaceutical process. Compared with traditional methods (taking approximately 14 weeks) and laboratory simulation methods (taking approximately 4 weeks), GoSilico's digital twin software will, throughModel Development Based on Chromatographic Mechanismsmethod of`Significantly Improve the Efficiency of Biopharmaceutical Downstream Processing`-- inOne weekachieve a scalable and stable solution within, and reduce the consumption of experimental materials.

Upon completion of the acquisition, GoSilico's main products, GoSilico ChromX and GoSilico DSPX, will retain their names but will be immediately integrated into Cytiva's existing product portfolio.

About Danaher:

Danaher is a global innovator in science and technology, dedicated to helping our customers worldwide tackle complex challenges and improve quality of life. In highly demanding and attractive sectors such as health, environmental, and industrial applications, we are home to a portfolio of world-class brands. Danaher Corporation comprises more than 20 operating companies globally, with over 60,000 employees. Our diverse team is united by a shared culture and operating system—the Danaher Business System (DBS)—and a common purpose: to realize life's unlimited potential.

For more information, please visit danaher.com.cn or follow the "Danaher" WeChat Official Account.

About Cytiva:

Cytiva is a pioneer in the global life sciences industry, with 8,000 employees across more than 40 countries and regions worldwide, dedicated to advancing unprecedented technologies and accelerating extraordinary therapies. As a trusted partner to its customers, Cytiva focuses on life science and biotechnology research to enable the development of innovative vaccines, biologics, and novel cell and gene therapies. By enhancing the speed, efficiency, and capacity of drug development and bioprocessing, Cytiva supports the development and manufacturing of transformative medicines and therapies to benefit patients globally. Please visit cytiva.com.cn for more information.

About Pall Corporation:

Pall Corporation is an operating company within the Life Sciences platform of Danaher Corporation (NYSE: DHR). Pall’s global workforce is united in its commitment to solving customer challenges in filtration, separation, and purification, and advancing technologies for health, safety, and environmental protection. Pall provides a comprehensive portfolio of technologies and solutions designed to safeguard health, protect critical operating assets, enhance product quality, and reduce emissions and waste. Pall’s Life Sciences and Industrial teams specialize in serving a wide range of customers across various industries, including biotechnology, pharmaceuticals, healthcare, food and beverage, laboratories, microelectronics, aerospace, oil and petrochemicals, chemicals, automotive, and power. For more information, please visit the WeChat Official Account “Pall China” or the official website.www.pall.comandwww.pall.cn。